The genomic and epigenomic landscape in thymic carcinoma

Motonobu Saito, Yutaka Fujiwara, Tetsuhiko Asao, Takayuki Honda, Yoko Shimada, Yae Kanai, Koji Tsuta, Koji Kono, Shunichi Watanabe, Yuichiro Ohe, Takashi Kohno

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Thymic carcinoma (TC) is a rare cancer whose genomic features have been examined in only a limited number of patients of European descent. Here, we characterized both genomic and epigenomic aberrations by whole exome sequencing, RNA sequencing, methylation array and copy number analyses in TCs from Asian patients and compared them with those in TCs from USA/European patients. Samples analyzed were 10 pairs of snap-frozen surgical specimens of cancerous and non-cancerous thymic tissue. All 10 cases were Japanese patients treated at the National Cancer Center Hospital, Japan, between 1994 and 2010. Mutational signature analysis indicated that the accumulation of age-related mutations drive TC development. We identified recurrent somatic mutations in TET2, CYLD, SETD2, TP53, FBXW7, HRAS and RB1, and no mutations in GTF2I, supporting the hypothesis that TC and thymoma are distinguishable by their genetic profiles. TCs with TET2 mutations had more hypermethylated genes than those without, and hyper-methylation was associated with downregulation of gene expression. Focal genome copy number gains, associated with elevated gene expression, were observed at the KIT (which is known to drive thymic carcinogenesis) and AHNAK2 gene loci. Taken together, the results suggest that the molecular processes leading to TC depend on the accumulation of genetic and epigenetic aberrations. In addition, epigenetic dysregulation as a result of the TET2 mutation was observed in a subset of TCs.

Original languageEnglish
Article numberbgx094
Pages (from-to)1084-1091
Number of pages8
JournalCarcinogenesis
Volume38
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Thymoma
Epigenomics
Mutation
Methylation
Exome
RNA Sequence Analysis
Gene Expression
Cancer Care Facilities
Genes
Japan
Carcinogenesis
Down-Regulation
Genome
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Saito, M., Fujiwara, Y., Asao, T., Honda, T., Shimada, Y., Kanai, Y., ... Kohno, T. (2017). The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis, 38(11), 1084-1091. [bgx094]. https://doi.org/10.1093/carcin/bgx094

The genomic and epigenomic landscape in thymic carcinoma. / Saito, Motonobu; Fujiwara, Yutaka; Asao, Tetsuhiko; Honda, Takayuki; Shimada, Yoko; Kanai, Yae; Tsuta, Koji; Kono, Koji; Watanabe, Shunichi; Ohe, Yuichiro; Kohno, Takashi.

In: Carcinogenesis, Vol. 38, No. 11, bgx094, 01.11.2017, p. 1084-1091.

Research output: Contribution to journalArticle

Saito, M, Fujiwara, Y, Asao, T, Honda, T, Shimada, Y, Kanai, Y, Tsuta, K, Kono, K, Watanabe, S, Ohe, Y & Kohno, T 2017, 'The genomic and epigenomic landscape in thymic carcinoma', Carcinogenesis, vol. 38, no. 11, bgx094, pp. 1084-1091. https://doi.org/10.1093/carcin/bgx094
Saito M, Fujiwara Y, Asao T, Honda T, Shimada Y, Kanai Y et al. The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis. 2017 Nov 1;38(11):1084-1091. bgx094. https://doi.org/10.1093/carcin/bgx094
Saito, Motonobu ; Fujiwara, Yutaka ; Asao, Tetsuhiko ; Honda, Takayuki ; Shimada, Yoko ; Kanai, Yae ; Tsuta, Koji ; Kono, Koji ; Watanabe, Shunichi ; Ohe, Yuichiro ; Kohno, Takashi. / The genomic and epigenomic landscape in thymic carcinoma. In: Carcinogenesis. 2017 ; Vol. 38, No. 11. pp. 1084-1091.
@article{8433c8abca8849be8552d952c1c67c2d,
title = "The genomic and epigenomic landscape in thymic carcinoma",
abstract = "Thymic carcinoma (TC) is a rare cancer whose genomic features have been examined in only a limited number of patients of European descent. Here, we characterized both genomic and epigenomic aberrations by whole exome sequencing, RNA sequencing, methylation array and copy number analyses in TCs from Asian patients and compared them with those in TCs from USA/European patients. Samples analyzed were 10 pairs of snap-frozen surgical specimens of cancerous and non-cancerous thymic tissue. All 10 cases were Japanese patients treated at the National Cancer Center Hospital, Japan, between 1994 and 2010. Mutational signature analysis indicated that the accumulation of age-related mutations drive TC development. We identified recurrent somatic mutations in TET2, CYLD, SETD2, TP53, FBXW7, HRAS and RB1, and no mutations in GTF2I, supporting the hypothesis that TC and thymoma are distinguishable by their genetic profiles. TCs with TET2 mutations had more hypermethylated genes than those without, and hyper-methylation was associated with downregulation of gene expression. Focal genome copy number gains, associated with elevated gene expression, were observed at the KIT (which is known to drive thymic carcinogenesis) and AHNAK2 gene loci. Taken together, the results suggest that the molecular processes leading to TC depend on the accumulation of genetic and epigenetic aberrations. In addition, epigenetic dysregulation as a result of the TET2 mutation was observed in a subset of TCs.",
author = "Motonobu Saito and Yutaka Fujiwara and Tetsuhiko Asao and Takayuki Honda and Yoko Shimada and Yae Kanai and Koji Tsuta and Koji Kono and Shunichi Watanabe and Yuichiro Ohe and Takashi Kohno",
year = "2017",
month = "11",
day = "1",
doi = "10.1093/carcin/bgx094",
language = "English",
volume = "38",
pages = "1084--1091",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The genomic and epigenomic landscape in thymic carcinoma

AU - Saito, Motonobu

AU - Fujiwara, Yutaka

AU - Asao, Tetsuhiko

AU - Honda, Takayuki

AU - Shimada, Yoko

AU - Kanai, Yae

AU - Tsuta, Koji

AU - Kono, Koji

AU - Watanabe, Shunichi

AU - Ohe, Yuichiro

AU - Kohno, Takashi

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Thymic carcinoma (TC) is a rare cancer whose genomic features have been examined in only a limited number of patients of European descent. Here, we characterized both genomic and epigenomic aberrations by whole exome sequencing, RNA sequencing, methylation array and copy number analyses in TCs from Asian patients and compared them with those in TCs from USA/European patients. Samples analyzed were 10 pairs of snap-frozen surgical specimens of cancerous and non-cancerous thymic tissue. All 10 cases were Japanese patients treated at the National Cancer Center Hospital, Japan, between 1994 and 2010. Mutational signature analysis indicated that the accumulation of age-related mutations drive TC development. We identified recurrent somatic mutations in TET2, CYLD, SETD2, TP53, FBXW7, HRAS and RB1, and no mutations in GTF2I, supporting the hypothesis that TC and thymoma are distinguishable by their genetic profiles. TCs with TET2 mutations had more hypermethylated genes than those without, and hyper-methylation was associated with downregulation of gene expression. Focal genome copy number gains, associated with elevated gene expression, were observed at the KIT (which is known to drive thymic carcinogenesis) and AHNAK2 gene loci. Taken together, the results suggest that the molecular processes leading to TC depend on the accumulation of genetic and epigenetic aberrations. In addition, epigenetic dysregulation as a result of the TET2 mutation was observed in a subset of TCs.

AB - Thymic carcinoma (TC) is a rare cancer whose genomic features have been examined in only a limited number of patients of European descent. Here, we characterized both genomic and epigenomic aberrations by whole exome sequencing, RNA sequencing, methylation array and copy number analyses in TCs from Asian patients and compared them with those in TCs from USA/European patients. Samples analyzed were 10 pairs of snap-frozen surgical specimens of cancerous and non-cancerous thymic tissue. All 10 cases were Japanese patients treated at the National Cancer Center Hospital, Japan, between 1994 and 2010. Mutational signature analysis indicated that the accumulation of age-related mutations drive TC development. We identified recurrent somatic mutations in TET2, CYLD, SETD2, TP53, FBXW7, HRAS and RB1, and no mutations in GTF2I, supporting the hypothesis that TC and thymoma are distinguishable by their genetic profiles. TCs with TET2 mutations had more hypermethylated genes than those without, and hyper-methylation was associated with downregulation of gene expression. Focal genome copy number gains, associated with elevated gene expression, were observed at the KIT (which is known to drive thymic carcinogenesis) and AHNAK2 gene loci. Taken together, the results suggest that the molecular processes leading to TC depend on the accumulation of genetic and epigenetic aberrations. In addition, epigenetic dysregulation as a result of the TET2 mutation was observed in a subset of TCs.

UR - http://www.scopus.com/inward/record.url?scp=85032750366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032750366&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgx094

DO - 10.1093/carcin/bgx094

M3 - Article

VL - 38

SP - 1084

EP - 1091

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 11

M1 - bgx094

ER -